BioMarin was ranked fourth on the 2019 list of "America's Best Midsize Employers" by Forbe's magazine
Jean-Jacques Bienaimé (76) – 1st Alumnus with the title of ESCP Doctor Honoris Causa – ESCP
Jean Jacques Bienaime Sells 1,500 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock - Opera News
BioMarin Pharmaceutical (NASDAQ: BMRN) wins FDA approval for $700,000 Batten disease drug Brineura - San Francisco Business Times
Jennifer Bienaime with Jean-Jacques Bienaime
Jean Jacques Bienaime vs Heather Bresch | Comparably
Search Images - Patrick McMullan
3.5: Testimony from Jean-Jacques Bienaimé (CEO - BioMarin Pharmaceutical) - Unit 3: Investing in Europe | Coursera
Bay Area Biotech 2015: The I-List — Tracking the most innovative biotechnology in the Bay Area - San Francisco Business Times
Jean-Jacques Bienaimé (76) – 1st Alumnus with the title of ESCP Doctor Honoris Causa – ESCP
Jennifer Bienaime with Jean-Jacques Bienaime
Rare Diseases | LOTUS EDITIONS
Jean-Jacques Bienaime with Jennifer Kano
BioMarin Pharmaceutical buys Zacharon for $10 million - San Francisco Business Times
Jean-Jacques Bienaime - Crunchbase Person Profile
Jean-Jacques Bienaime
BioMarin Pharmaceutical 1Q loss rises amid higher expenses for product launch
Jean-Jacques Bienaimé - Advisor at Longwood Fund | The Org
Jean Jacques Bienaime – North Bay Leadership Council
Jean-Jacques Bienaimé | Health Evolution
People | Nature Biotechnology
Jean-Jacques Bienaimé | Leadership Team - BioMarin
BioMarin's CEO On Its Product Pipeline
BioMarin CEO Jean-Jacques Bienaimé - Xconomy
The Rocky Journey To Refocusing BioMarin
jean-jacques-bienaime-biomarin-ceo | North Bay Life Science Alliance
Jean-Jacques Bienaimé - Chairman & CEO at BioMarin Pharmaceutical | The Org
